Učitavanje...
The impact of early phase price agreements on prices of orphan drugs
BACKGROUND: Innovative orphan drugs often have an incremental cost-effectiveness ratio (ICER) which is higher than the maximum threshold for reimbursement. Payers have limited budgets and often cannot pay the full price of a new product, but pharmaceutical and biotechnology companies require a minim...
Spremljeno u:
| Izdano u: | BMC Health Serv Res |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7953706/ https://ncbi.nlm.nih.gov/pubmed/33711994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12913-021-06208-7 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|